Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico’s proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics.
Acrivon draws in $130M; Vincerx Pharma’s Ph1 metastatic tumor data
Acrivon raises $130M PIPE: The precision oncology biotech brought in the money from RA Capital, Perceptive Advisors and other investors. Its stock $ACRV was up
April 10, 2024